Andrew W Mulcahy1, Sharon-Lise Normand1, John W Newcomer1, Benjamin Colaiaco1, Julie M Donohue1, Judith R Lave1, Emmett Keeler1, Mark J Sorbero1, Marcela Horvitz-Lennon1. 1. Dr. Mulcahy is with RAND Corporation, Arlington, Virginia. Dr. Normand is with the Department of Health Care Policy, Harvard Medical School, and with the Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston. Dr. Newcomer is with the Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. Mr. Colaiaco is with the Allegheny Health Network, Pittsburgh. Dr. Keeler is with RAND Corporation, Santa Monica, California, where Mr. Colaiaco was affiliated at the time of this study. Dr. Donohue and Dr. Lave are with the Graduate School of Public Health, University of Pittsburgh, Pittsburgh. Mr. Sorbero is with RAND Corporation, Pittsburgh. Dr. Horvitz-Lennon is with RAND Corporation, Boston.
Abstract
OBJECTIVE: Second-generation antipsychotics increase the risk of diabetes and other metabolic conditions among individuals with schizophrenia. Although metabolic testing is recommended to reduce this risk, low testing rates have prompted concerns about negative health consequences and downstream medical costs. This study simulated the effect of increasing metabolic testing rates on ten-year prevalence rates of prediabetes and diabetes (diabetes conditions) and their associated health care costs. METHODS: A microsimulation model (N=21,491 beneficiaries) with a ten-year time horizon was used to quantify the impacts of policies that increased annual testing rates in a Medicaid population with schizophrenia. Data sources included California Medicaid data, National Health and Nutrition Examination Survey data, and the literature. In the model, metabolic testing increased diagnosis of diabetes conditions and diagnosis prompted prescribers to switch patients to lower-risk antipsychotics. Key inputs included observed diagnoses, prescribing rates, annual testing rates, imputed rates of undiagnosed diabetes conditions, and literature-based estimates of policy effectiveness. RESULTS: Compared with 2009 annual testing rates, ten-year outcomes for policies that achieved universal testing reduced exposure to higher-risk antipsychotics by 14%, time to diabetes diagnosis by 57%, and diabetes prevalence by .6%. These policies were associated with higher spending because of testing and earlier treatment. CONCLUSIONS: The model showed that policies promoting metabolic testing provided an effective approach to improve the safety of second-generation antipsychotic prescribing in a Medicaid population with schizophrenia; however, the policies led to additional costs at ten years. Simulation studies are a useful source of information on the potential impacts of these policies.
OBJECTIVE: Second-generation antipsychotics increase the risk of diabetes and other metabolic conditions among individuals with schizophrenia. Although metabolic testing is recommended to reduce this risk, low testing rates have prompted concerns about negative health consequences and downstream medical costs. This study simulated the effect of increasing metabolic testing rates on ten-year prevalence rates of prediabetes and diabetes (diabetes conditions) and their associated health care costs. METHODS: A microsimulation model (N=21,491 beneficiaries) with a ten-year time horizon was used to quantify the impacts of policies that increased annual testing rates in a Medicaid population with schizophrenia. Data sources included California Medicaid data, National Health and Nutrition Examination Survey data, and the literature. In the model, metabolic testing increased diagnosis of diabetes conditions and diagnosis prompted prescribers to switch patients to lower-risk antipsychotics. Key inputs included observed diagnoses, prescribing rates, annual testing rates, imputed rates of undiagnosed diabetes conditions, and literature-based estimates of policy effectiveness. RESULTS: Compared with 2009 annual testing rates, ten-year outcomes for policies that achieved universal testing reduced exposure to higher-risk antipsychotics by 14%, time to diabetes diagnosis by 57%, and diabetes prevalence by .6%. These policies were associated with higher spending because of testing and earlier treatment. CONCLUSIONS: The model showed that policies promoting metabolic testing provided an effective approach to improve the safety of second-generation antipsychotic prescribing in a Medicaid population with schizophrenia; however, the policies led to additional costs at ten years. Simulation studies are a useful source of information on the potential impacts of these policies.
Entities:
Keywords:
Antipsychotics; Quality of care; Schizophrenia; antipsychotics; metabolic testing; simulation
Authors: T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2011-07-18 Impact factor: 18.112
Authors: Eric Hermes; Henry Nasrallah; Vicki Davis; Jonathan Meyer; Joseph McEvoy; Donald Goff; Sonia Davis; T Scott Stroup; Marvin Swartz; Jeffrey Lieberman; Robert Rosenheck Journal: Schizophr Res Date: 2011-02-21 Impact factor: 4.939
Authors: Ginger E Nicol; Elizabeth J Campagna; Lauren D Garfield; John W Newcomer; Joseph J Parks; Elaine H Morrato Journal: Psychiatr Serv Date: 2015-09-01 Impact factor: 3.084
Authors: Hua Jin; Pei-an Betty Shih; Shahrokh Golshan; Sunder Mudaliar; Robert Henry; Danielle K Glorioso; Stephan Arndt; Helena C Kraemer; Dilip V Jeste Journal: J Clin Psychiatry Date: 2012-11-27 Impact factor: 4.384
Authors: N Waugh; G Scotland; P McNamee; M Gillett; A Brennan; E Goyder; R Williams; A John Journal: Health Technol Assess Date: 2007-05 Impact factor: 4.014
Authors: John W Newcomer; Joao Alberto Campos; Ronald N Marcus; Christopher Breder; Robert M Berman; Wendy Kerselaers; Gilbert J L'italien; Marleen Nys; William H Carson; Robert D McQuade Journal: J Clin Psychiatry Date: 2008-07 Impact factor: 4.384